Mitotic Arrest-Deficient 2 Like 2 (MAD2L2) Interacts with Effector Protein EspF

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Sep 28

PMID 34575120

Citations 1

Authors

Amin Tahoun

Hanem El-Sharkawy

Samar M Moustafa

Lina Jamil M Abdel-Hafez

Ashraf Albrakati

Manfred Koegl

Juergen Haas

Arvind Mahajan

David L Gally

Ehab Kotb Elmahallawy

Affiliations

Soon will be listed here.

Abstract

(EPEC) and (EHEC) are considered emerging zoonotic pathogens of worldwide distribution. The pathogenicity of the bacteria is conferred by multiple virulence determinants, including the locus of enterocyte effacement (LEE) pathogenicity island, which encodes a type III secretion system (T3SS) and effector proteins, including the multifunctional secreted effector protein (EspF). EspF sequences differ between EPEC and EHEC serotypes in terms of the number and residues of SH3-binding polyproline-rich repeats and N-terminal localization sequence. The aim of this study was to discover additional cellular interactions of EspF that may play important roles in colonization using the Yeast two-hybrid screening system (Y2H). Y2H screening identified the anaphase-promoting complex inhibitor Mitotic Arrest-Deficient 2 Like 2 (MAD2L2) as a host protein that interacts with EspF. Using LUMIER assays, MAD2L2 was shown to interact with EspF variants from EHEC O157:H7 and O26:H11 as well as EPEC O127:H6. MAD2L2 is targeted by the non-homologous effector protein invasion plasmid antigen B (IpaB) to halt the cell cycle and limit epithelial cell turnover. Therefore, we postulate that interactions between EspF and MAD2L2 serve a similar function in promoting EPEC and EHEC colonization, since cellular turnover is a key method for bacteria removal from the epithelium. Future work should investigate the biological importance of this interaction that could promote the colonization of EPEC and EHEC in the host.

Citing Articles

REV7: a small but mighty regulator of genome maintenance and cancer development.

Maggs L, McVey M Front Oncol. 2025; 14:1516165.

PMID: 39839778 PMC: 11747621. DOI: 10.3389/fonc.2024.1516165.

Enterohemorrhagic effector EspF triggers oxidative DNA lesions in intestinal epithelial cells.

Fang Y, Fu M, Li X, Zhang B, Wan C Infect Immun. 2024; 92(4):e0000124.

PMID: 38415639 PMC: 11003234. DOI: 10.1128/iai.00001-24.

References

Alto N, Weflen A, Rardin M, Yarar D, Lazar C, Tonikian R . The type III effector EspF coordinates membrane trafficking by the spatiotemporal activation of two eukaryotic signaling pathways. J Cell Biol. 2007; 178(7):1265-78. PMC: 2064658. DOI: 10.1083/jcb.200705021. View

Kassa E, Zlotkin-Rivkin E, Friedman G, Ramachandran R, Melamed-Book N, Weiss A . Enteropathogenic Escherichia coli remodels host endosomes to promote endocytic turnover and breakdown of surface polarity. PLoS Pathog. 2019; 15(6):e1007851. PMC: 6615643. DOI: 10.1371/journal.ppat.1007851. View

Fu M, Liang S, Wu J, Hua Y, Chen H, Zhang Z . An Effector Protein EspF May Induce Host DNA Damage via Interaction With SMC1. Front Microbiol. 2021; 12:682064. PMC: 8188558. DOI: 10.3389/fmicb.2021.682064. View

Bhat A, Wu Z, Maher V, McCormick J, Xiao W . Rev7/Mad2B plays a critical role in the assembly of a functional mitotic spindle. Cell Cycle. 2015; 14(24):3929-38. PMC: 4825701. DOI: 10.1080/15384101.2015.1120922. View

Mohr K, Koegl M . High-throughput yeast two-hybrid screening of complex cDNA libraries. Methods Mol Biol. 2012; 812:89-102. DOI: 10.1007/978-1-61779-455-1_5. View

Cheung H, Chun A, Wang Q, Deng W, Hu L, Guan X . Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res. 2006; 66(8):4357-67. DOI: 10.1158/0008-5472.CAN-05-3602. View

Hong C, Chou Y, Lin Y, Wu C . MAD2B, a novel TCF4-binding protein, modulates TCF4-mediated epithelial-mesenchymal transdifferentiation. J Biol Chem. 2009; 284(29):19613-22. PMC: 2740587. DOI: 10.1074/jbc.M109.005017. View

Fields S, Song O . A novel genetic system to detect protein-protein interactions. Nature. 1989; 340(6230):245-6. DOI: 10.1038/340245a0. View

El-Gohary F, Abdel-Hafez L, Zakaria A, Shata R, Tahoun A, El-Mleeh A . Enhanced Antibacterial Activity of Silver Nanoparticles Combined with Hydrogen Peroxide Against Multidrug-Resistant Pathogens Isolated from Dairy Farms and Beef Slaughterhouses in Egypt. Infect Drug Resist. 2020; 13:3485-3499. PMC: 7550212. DOI: 10.2147/IDR.S271261. View

10.

Donnenberg M, Finlay B . Combating enteropathogenic Escherichia coli (EPEC) infections: the way forward. Trends Microbiol. 2013; 21(7):317-9. PMC: 4312613. DOI: 10.1016/j.tim.2013.05.003. View

11.

Tahoun A, Siszler G, Spears K, McAteer S, Tree J, Paxton E . Comparative analysis of EspF variants in inhibition of Escherichia coli phagocytosis by macrophages and inhibition of E. coli translocation through human- and bovine-derived M cells. Infect Immun. 2011; 79(11):4716-29. PMC: 3257939. DOI: 10.1128/IAI.00023-11. View

12.

Sczaniecka M, Hardwick K . The spindle checkpoint: how do cells delay anaphase onset?. SEB Exp Biol Ser. 2008; 59:243-56. View

13.

Marima R, Hull R, Penny C, Dlamini Z . Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. Mutat Res Rev Mutat Res. 2021; 787:108376. DOI: 10.1016/j.mrrev.2021.108376. View

14.

Torres A, Amaral M, Bentancor L, Galli L, Goldstein J, Kruger A . Recent Advances in Shiga Toxin-Producing Research in Latin America. Microorganisms. 2018; 6(4). PMC: 6313304. DOI: 10.3390/microorganisms6040100. View

15.

Dean P, Scott J, Knox A, Quitard S, Watkins N, Kenny B . The enteropathogenic E. coli effector EspF targets and disrupts the nucleolus by a process regulated by mitochondrial dysfunction. PLoS Pathog. 2010; 6(6):e1000961. PMC: 2891835. DOI: 10.1371/journal.ppat.1000961. View

16.

Chen H, Frankel G . Enteropathogenic Escherichia coli: unravelling pathogenesis. FEMS Microbiol Rev. 2005; 29(1):83-98. DOI: 10.1016/j.femsre.2004.07.002. View

17.

Muto T, Obita T, Abe Y, Shodai T, Endo T, Kohda D . NMR identification of the Tom20 binding segment in mitochondrial presequences. J Mol Biol. 2001; 306(2):137-43. DOI: 10.1006/jmbi.2000.4397. View

18.

Peralta-Ramirez J, Hernandez J, Manning-Cela R, Luna-Munoz J, Garcia-Tovar C, Nougayrede J . EspF Interacts with nucleation-promoting factors to recruit junctional proteins into pedestals for pedestal maturation and disruption of paracellular permeability. Infect Immun. 2008; 76(9):3854-68. PMC: 2519440. DOI: 10.1128/IAI.00072-08. View

19.

Hua Y, Yan K, Wan C . Clever Cooperation: Interactions Between EspF and Host Proteins. Front Microbiol. 2018; 9:2831. PMC: 6262023. DOI: 10.3389/fmicb.2018.02831. View

20.

Torres A . Escherichia coli diseases in Latin America-a 'One Health' multidisciplinary approach. Pathog Dis. 2017; 75(2). DOI: 10.1093/femspd/ftx012. View